title: Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience.
abstract: Several reports have emphasized the risk of hepatitis B virus (HBV) reactivation in patients with lymphoproliferative disorders undergoing cytotoxic treatment. To determine the prevalence of occult B infection (OBI) in a population with chronic lymphocytic leukemia (CLL) and management with universal prophylaxis (UP) in all patients undergoing chemoimmunotherapy or targeted prophylaxis (TP) in patients experiencing seroreversion during therapy, we analyzed 397 patients with CLL from our database. The prevalence of OBI in our patients with CLL was 8.6% (34 patients). When comparing patients with OBI/CLL with those with CLL, we did not find any statistical difference among clinical-biological parameters and time dependent endpoints except for a lower peripheral blood lymphocyte count in the OBI/CLL group (p = 0.036). From 2000 to 2010 careful follow-up and TP were adopted; two out of 10 patients (20%) showed seroreversion. From June 2010 we adopted UP during and 12 months after immunosuppressive treatment in all patients with CLL with OBI; no evidence of seroreversion was detected.
authors: a Department of Hematology , Catholic University of the Sacre Heart , Rome , Italy.
authors: Luca
authors: L
authors: Laurenti
authors: a Department of Hematology , Catholic University of the Sacre Heart , Rome , Italy.
authors: Francesco
authors: F
authors: Autore
authors: a Department of Hematology , Catholic University of the Sacre Heart , Rome , Italy.
authors: Idanna
authors: I
authors: Innocenti
authors: a Department of Hematology , Catholic University of the Sacre Heart , Rome , Italy.
authors: Barbara
authors: B
authors: Vannata
authors: a Department of Hematology , Catholic University of the Sacre Heart , Rome , Italy.
authors: Nicola
authors: N
authors: Piccirillo
authors: a Department of Hematology , Catholic University of the Sacre Heart , Rome , Italy.
authors: Federica
authors: F
authors: Sorà
authors: b Department of Laboratory Medicine , Catholic University of the Sacre Heart , Rome , Italy.
authors: Domenico
authors: D
authors: Speziale
authors: c Internal Medicine, Catholic University of the Sacre Heart , Rome , Italy.
authors: Maurizio
authors: M
authors: Pompili
authors: d ICGEB Outstation-Monterotondo, CNR Campus "A. Buzzati-Traverso" , Rome , Italy.
authors: Dimitar
authors: D
authors: Efremov
authors: a Department of Hematology , Catholic University of the Sacre Heart , Rome , Italy.
authors: Simona
authors: S
authors: Sica
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers; D019468:Disease Management; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D006515:Hepatitis B virus / Q000502:physiology; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012189:Retrospective Studies; D016896:Treatment Outcome; D014775:Virus Activation / Q000187:drug effects
chemical_list: D015415:Biomarkers
keywords: Lymphoid leukemia; chemotherapeutic approaches; immunotherapeutic approaches